Ebola

Medical Tent Market - Global Outlook and Forecast 2023-2028: Increasing Demand for Negative Pressure Isolation Tents Boosts Sector

Retrieved on: 
Tuesday, March 7, 2023
Aurora, History, Snow, SARS, Tuberculosis, Johns Hopkins Children's Center, Nursing care plan, Boston Children's Hospital, Child, Patient, Decontamination, Measles, Maintenance, Influenza and Other Respiratory Viruses, Government, Respiratory syncytial virus, Infection, MERS, Cholera, COVID-19, Children's Hospital Colorado, Wind, Hospital, RSV, USD, Triage, Military personnel, Atmosphere, Static pressure, Ukrainians, Disaster, City, Ebola, Children's Hospital, Growth, Vaccine hesitancy, Non-governmental organization, Virus, Multi, NSR, Vaccine, Arms industry, Birth control, Pharmaceutical industry

The global medical tent market is expected to rise considerably due to increased usage of tents in the military segment, medical emergencies, and rescue operations.

Key Points: 
  • The global medical tent market is expected to rise considerably due to increased usage of tents in the military segment, medical emergencies, and rescue operations.
  • To remain competitive in the medical tent market, vendors have been focusing on meeting the challenges associated with traditional medical tents.
  • AKS Industries, UTILIS, Stretch Event Tents USA, and Instent Industries are some of the leading companies in the medical tent market offering negative pressure isolation tents.
  • Vendors are developing medical tents for various purposes, such as medical supplies storage, medical waste disposal tents, decontamination, and multipurpose tents.

EQS-News: Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors

Retrieved on: 
Wednesday, February 22, 2023
Stock dilution, Maintenance, EUR, ISIN, Immune system, Calendar, Redemption, Annual, Sofinnova, Marketing, UC, CFO, VWAP, Therapy, BPI, Investment, Patient, Sale, Research, Directeur sportif, K, Equity carve-out, Ulcerative colitis, Rheumatoid arthritis, Euronext Paris, CET, Ebola, INVU (song), Security (finance), Pharmaceutical industry, Bank, KREO (FM), Abivax

Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax said: “We are excited to announce today’s successful pricing of Abivax’s oversubscribed capital increase of EUR 130M, with a balanced mix of top-tier existing and new investors, mostly US biotech specialists.

Key Points: 
  • Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax said: “We are excited to announce today’s successful pricing of Abivax’s oversubscribed capital increase of EUR 130M, with a balanced mix of top-tier existing and new investors, mostly US biotech specialists.
  • The Abivax team is fully focused on making obefazimod rapidly accessible to all the patients in need.”
    Didier Blondel, CFO of Abivax, added: “We are extremely pleased to announce our successful EUR 130M capital increase at market price.
  • Abivax, once again, could attract new top-tier US and European biotech investors, including Great Point Partners, LLC, Deerfield Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and a few additional great names, as well as most of our existing US and European biotech investors.
  • Investors participating in the Capital Increase have not taken any lock-up undertakings relating to the shares subscribed in the framework of the Capital Increase.

KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment

Retrieved on: 
Monday, January 23, 2023
Research, Infectious Diseases, FDA, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Administration, MAPP, Human services, Office of Inspector General, U.S. Department of Health and Human Services, SUDV, Development, World Health Organization, Ebola, BARDA, Ebolavirus, KBI, Biomedical Advanced Research and Development Authority, Republic, Mapp Biopharmaceutical, Death, Administration for Strategic Preparedness and Response, Vaccine

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus (SUDV)*.

Key Points: 
  • KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus (SUDV)*.
  • KBI is playing an important role in supporting Mapp’s efforts by providing expedited product development support including analytical and manufacturing contributions across multiple global sites.
  • “SUDV is an urgent health crisis, and KBI is pleased to subcontract with Mapp, expediting the availability of MBP134 to make an impact,” said Dr. Abdelaziz Toumi, Chief Business Officer of KBI Biopharma and Selexis SA.
  • Currently, there is no cure for Sudan ebolavirus virus disease, which has a fatality rate of around 50%.

AHF Salutes Uganda on Ebola Response Win

Retrieved on: 
Thursday, January 12, 2023
Infectious Diseases, AIDS, Other Health, Hospitals, Health, Mentorship, Infection, AIDS, Public health, WHO, Ebola, Government, Ministry, AIDS Healthcare Foundation, Emergency, Ministry of Health (Uganda), AHF, Fatality, Contact tracing, Multimedia, Vaccine, Health

View the full release here: https://www.businesswire.com/news/home/20230112005436/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230112005436/en/
    The Infection Prevention Control Coordinator of the Ministry of Health takes AHF Uganda Cares Mentors through Ebola infection prevention control protocol.
  • (Photo: Business Wire)
    "I salute Uganda for so effectively controlling this outbreak despite the fact that it invaded its largest city.
  • This was the eighth time Uganda had faced an Ebola outbreak since 2000, when the nation saw its first and deadliest occurrence, which left more than 200 people dead.
  • This win by Uganda again demonstrates that there are lessons to be learnt from the African continent in containing, averting, and responding to public health emergencies.

Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

Retrieved on: 
Thursday, January 12, 2023
Biomedical Advanced Research and Development Authority, Office of Inspector General, U.S. Department of Health and Human Services, Finan of Lindisfarne, World Health Organization, Development, Fever, U.S. Department of Commerce Office of Security, Administration, Ebola, Human services, Vaccine, Sabin Vaccine Institute, Partnership, Death, BARDA, ASPR, United States Department of Health and Human Services

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

Key Points: 
  • There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.
  • These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.
  • The country declared the Ebola Sudan outbreak had ended on January 11 , four months after the first confirmed case.
  • “Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan.

The Native Antigen Company Expands Infectious Disease Portfolio to Include Sudan Ebolavirus Boniface 1976 Glycoprotein

Retrieved on: 
Thursday, December 8, 2022
Medical Devices, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Antigen, Ebolavirus, SEBOV, Infection, HEK 293 cells, Research, Ebola, Disease, Antibody, Cell, Human, Vaccine, Immunoassay, Mortality, Health, EBOV, Sudan ebolavirus

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the worlds leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP).

Key Points: 
  • The Native Antigen Company (part of LGC Clinical Diagnostics), one of the worlds leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP).
  • Sudan Ebolavirus is a species of ebolavirus responsible for severe disease in humans, Ebola haemorrhagic fever, for which there are currently no licensed vaccines or treatments available.
  • The Native Antigen Companys SEBOV GP is designed for use in immunoassay and vaccine development to support research into the deadly disease.
  • For further information about The Native Antigen Companys Sudan Ebolavirus Boniface 1976 Glycoprotein, please visit: https://thenativeantigencompany.com/products/ebola-virus-envelope-glycop...

Rockefeller Foundation President, Rajiv J. Shah, to Present at the AAGL Global Congress on Minimally Invasive Gynecologic Surgery

Retrieved on: 
Wednesday, November 23, 2022
Aurora, Public policy, Ebola, Surgeon, Bill, Physician, Rockefeller Foundation, Wharton School of the University of Pennsylvania, AAGL, State, Marketing, Business, Woman, Immunization, Health, University, Research, American Academy, Medicine, Foundation (nonprofit), Keynote, Congress, Science, Communications manager, USAID, American Academy of Arts and Sciences, International, Distinguished Service Award, Safety, Education, Pharmaceutical industry, MIGS

CYPRESS, Calif., Nov. 23, 2022 /PRNewswire-PRWeb/ -- AAGL Global Congress will welcome physicians from all over the world online and live at the Gaylord Rockies Convention Center in Aurora, Colorado, USA, December 1-4, 2022. Participants will enjoy a robust, four-day, scientific program, thoughtfully developed by Dr. Andrew I. Sokol and the Scientific Program Committee. The theme of this year's Global Congress, "Dissemination of MIGS Care: Improving Access for All" captures AAGL's global vision to combine the wealth of experience of the association's worldwide physician membership and best identify ways to improve access to quality MIGS care for all women, including those in underserved populations.

Key Points: 
  • Dr. Rajiv J. Shah, President of the Rockefeller Foundation and former Administrator of USAID under President Obama, will present a Keynote Address at the American Association of Gynecologic Laparoscopists (AAGL) 51st Global Congress on Minimally Invasive Gynecologic Surgery (MIGS) on December 3, 2022.
  • AAGL's Global Congress, the premier scientific conference for gynecologic surgeons from around the world, offers high-quality education and cutting-edge best practices in MIGS.
  • The AAGL Global Congress on MIGS is the premier academic event of the year for personal and professional development in Minimally Invasive Gynecologic Surgery.
  • 2022 AAGL Global Congress Highlight Video: https://youtu.be/tnfv5I1LLLg
    AAGL is an international professional medical association of laparoscopic surgeons and the global leader in minimally invasive gynecologic surgery.

HEALTH RESEARCH FOUNDATION ANNOUNCES RECIPIENT OF ITS MEDAL OF HONOUR

Retrieved on: 
Wednesday, November 16, 2022
Human, World Health Organization, World, HRF, MERS, Ebola, University, Immunization, Department, Code, Education, Research, Mount Sinai Hospital, Association, McGeer, Patient, COVID-19, Policy, Medal of Honor, Infection, Vaccine, Public policy, Medical laboratory, SARS, Medical device, Medicine, Pharmaceutical industry, Indspire

OTTAWA, ON, Nov. 15, 2022 /CNW/ - The Health Research Foundation (HRF) of Innovative Medicines Canada is pleased to announce that Dr. Allison McGeer is the recipient of its distinguished Medal of Honour.

Key Points: 
  • OTTAWA, ON, Nov. 15, 2022 /CNW/ - The Health Research Foundation (HRF) of Innovative Medicines Canada is pleased to announce that Dr. Allison McGeer is the recipient of its distinguished Medal of Honour.
  • "The Health Research Foundation is extremely proud to present Dr. McGeer with its Medal of Honour.
  • "The HRF has been a longstanding pillar in the health research community and it's an honour to receive this recognition."
  • The Health Research Foundation (HRF) of Innovative Medicines Canada is a non-profit organization that invests in Canadian academic health research and promotes the value of research-driven health innovation in Canada.

Healthcare and Medical Leaders Gather to Shape the Future of Global Health

Retrieved on: 
Friday, November 11, 2022
CEO, Artificial intelligence, Ethics, Medtech, Global health, Assistant, Hong Kong Trade Development Council Trade Fairs, Hope, Government, Epidemic, Department, Telehealth, Industry, Heart rate, Global Health, Business, GBA, ESG, Health, Medicine, Blood pressure, Research, Mental health, Special, Hong Kong International Medical Devices and Supplies Fair, School, Deal flow, Royal commission, COVID-19, Robotics, Gleneagles Hospital, Health care, HKTDC, Solution, Institute, AI, MOU, Vaccine, Summit, Biotechnology, Efficiency, Communication, Public affairs, VR, HKSAR, Public health, Pandemic, SME, University College London, European Commission, COVID, Tutoring, Management, Medical device, Pharmaceutical industry, Healthcare, Clothing, Tax advisor, Ebola

Dr Peter K N Lam, Chairman of the HKTDC, said, "The importance of the medical and healthcare sector to the global economy cannot be overstated, especially during the past three years.

Key Points: 
  • Dr Peter K N Lam, Chairman of the HKTDC, said, "The importance of the medical and healthcare sector to the global economy cannot be overstated, especially during the past three years.
  • As markets across the world gradually recover from the fallout of the pandemic, the health crisis needs to be tackled in tandem.
  • The Summit featured more than 80 speakers, including healthcare officials and members from international organisations, scientists and medical experts, investors, business leaders, financial specialists and service providers.
  • The Medical Fair is co-organised by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA).

Ebola Outbreak Still A Risk As Designated Hospitals Can’t Treat Deadly Waste On-Site

Retrieved on: 
Monday, November 7, 2022
Infectious Diseases, Hospitals, Health, Healthcare Reform, Public Policy, Government, Cleveland Clinic, UCLA, Sterilization, Tuskegee Veterans Administration Medical Center, Transport, RMW, CAT, Waste management, Haulage, HHS, Federation, Method, Hopkins, Stanford University, Animal, Senior advisor, USDOT, Pacific Northwest, Ebla, Hospital, Incineration, Waste, CDC, OSHA, Awareness, EPA, Congress, Environmental remediation, Ebola

U.S. hospitals have been instructed to ramp up their preparedness plans, but many hospitals still arent able to sterilize the deadly Ebola waste on site.

Key Points: 
  • U.S. hospitals have been instructed to ramp up their preparedness plans, but many hospitals still arent able to sterilize the deadly Ebola waste on site.
  • However, 5 of the 13 special pathogen centers can NOT treat such waste on-site.
  • One of the greatest challenge hospitals faced during the last outbreak was handling Ebola waste, which became a prominent issue during the Ebola crisis that came under scrutiny by the press and Congress.
  • Ebola waste is classified as Category A by the US Department of Transportation (USDOT).